Magenta Therapeutics Inc (OQ:MGTA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 100 Technology Sq Fl 5
CAMBRIDGE MA 02139-3585
Tel: N/A
Website: https://www.magentatx.com
IR: See website
<
Key People
Michael W. Bonney
Independent Chairman of the Board
Jason Gardner
President, Chief Executive Officer, Co-Founder, Director
Cindy Driscoll
Principal Financial Officer, Principal Accounting Officer, Vice President - Finance
Kristen Stants
Chief People Officer
Li Malmberg
Senior Vice President - Head of Manufacturing
John C. Davis
Chief Medical Officer, Head of Research and Development
Christina K. Isacson
Chief Business Officer
Zoran Zdraveski
Secretary and Chief Legal Officer
 
Business Overview
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company's products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company's C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
Financial Overview
For the six months ended 30 June 2020, Magenta Therapeutics Inc revenues was not reported. Net loss increased 20% to $39.1M. Higher net loss reflects Research and development - Balancin increase of 16% to $24.8M (expense), General and increase of 24% to $11.2M (expense), Interest and other income, net decrease of 31% to $2.2M (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.93 to -$0.99.
Employees: 72 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $161.27M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$86.58M as of Jun 30, 2020
Net annual income (TTM): -$83.32M as of Jun 30, 2020
Free cash flow (TTM): -$63.85M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 48,252,724 as of Jul 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.